Robin Andrulevich
Personalreferent bei SANA BIOTECHNOLOGY, INC.
Profil
Robin Andrulevich is currently the Director at Washington Biotechnology & Biomedical Association and the Chief People Officer & Executive Vice President at Sana Biotechnology, Inc. In the past, Andrulevich worked as a Director at Acepodia Biotechnologies, Ltd., a Principal at Amazon.com, Inc., and as the Senior Vice President-People at Juno Therapeutics, Inc. Andrulevich completed an undergraduate degree at the University of Connecticut.
Aktive Positionen von Robin Andrulevich
Unternehmen | Position | Beginn |
---|---|---|
SANA BIOTECHNOLOGY, INC. | Personalreferent | 01.09.2018 |
Washington Biotechnology & Biomedical Association | Direktor/Vorstandsmitglied | 01.12.2017 |
Ehemalige bekannte Positionen von Robin Andrulevich
Unternehmen | Position | Ende |
---|---|---|
JUNO THERAPEUTICS INC | Personalreferent | 01.04.2018 |
Acepodia Biotechnologies, Ltd.
Acepodia Biotechnologies, Ltd. BiotechnologyHealth Technology Acepodia Biotechnologies, Ltd. engages in the development of cell therapies to treat patients with cancers. Its business information includes biotechnology service industry, intellectual property rights, and wholesale and retail trade of chemical raw materials. The company was founded by Patrick Yang, and by Sonny Hsiao on June 19, 2017 and is headquartered in Taipei, Taiwan. | Direktor/Vorstandsmitglied | - |
AMAZON.COM, INC. | Corporate Officer/Principal | - |
Ausbildung von Robin Andrulevich
University of Connecticut | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
AMAZON.COM, INC. | Retail Trade |
SANA BIOTECHNOLOGY, INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Juno Therapeutics, Inc.
Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
Washington Biotechnology & Biomedical Association | |
Acepodia Biotechnologies, Ltd.
Acepodia Biotechnologies, Ltd. BiotechnologyHealth Technology Acepodia Biotechnologies, Ltd. engages in the development of cell therapies to treat patients with cancers. Its business information includes biotechnology service industry, intellectual property rights, and wholesale and retail trade of chemical raw materials. The company was founded by Patrick Yang, and by Sonny Hsiao on June 19, 2017 and is headquartered in Taipei, Taiwan. | Health Technology |